Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
Cullinan Management (CGEM) Stock Price & Analysis
122 Followers
CGEM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.64 - $30.19
Previous Close$26.72
Volume866.94K
Average Volume (3M)743.41K
Market Cap
$1.15B
Enterprise Value$688.28M
Total Cash (Recent Filing)$466.43M
Total Debt (Recent Filing)$3.99M
Price to Earnings (P/E)-7.2
Beta0.90
Next Earnings
Aug 08, 2024EPS Estimate
-$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.70
Shares Outstanding43,065,645
10 Day Avg. Volume851,702
30 Day Avg. Volume743,414
Standard Deviation0.18
R-Squared0.00
Alpha0.00464
Financial Highlights & Ratios
Price to Book (P/B)2.42
Price to Sales (P/S)11507.14
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.29K
Enterprise Value/Gross Profit6.88K
Enterprise Value/Ebitda-5.08
Forecast
1Y Price Target
$33.83Price Target Upside42.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Cullinan Management News
PremiumCompany Announcements
Cullinan Management Welcomes David Meek to Board of Directors
PremiumCompany Announcements
Cullinan Management Names Mary Kay Fenton New CFO
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementEarly clinical results show CLN-978 induces rapid and deep B-cell depletion, indicating the drug's potential effectiveness in treating autoimmune diseases.
Market OpportunityCullinan's strategic focus on autoimmune indications for their CLN-978 program taps into a substantial market opportunity with a large unmet need, highlighted by an estimated $11B market in SLE.
Product DevelopmentCGEM's simpler bispecific T-cell engager (TCE) offers potential similar efficacy to CAR-T therapies, targeting large market indications for significant stock upside.
Bears Say
Clinical TrialsCullinan is discontinuing enrollment in the CLN-978 B-NHL study to focus on autoimmune diseases, following mixed results from the study.
Drug DevelopmentCGEM disclosed that they will no longer develop CLN-978 in Non Hodgkin's Lymphoma (NHL), discontinuing the ongoing Phase 1 trial.
Executive MovementCFO Jeff Trigilio will depart the company, although he will assist in the transition as a consultant until a new CFO is found.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $7.64 and its highest was $30.19 in the past 12 months.
What is Cullinan Management’s market cap?
Currently, no data Available
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is Aug 08, 2024 which is in 83 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on May 15, 2024. The company reported -$0.86 earnings per share for the quarter, beating the consensus estimate of -$0.99 by $0.13.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -$0.78.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 43,065,643 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.86 in its last earnings report, beating expectations of -$0.99. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cullinan Management?
Among the largest hedge funds holding Cullinan Management’s share is Caxton Associates LP. It holds Cullinan Management’s shares valued at N/A.
---
Cullinan Management Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (42.08% Upside)
$33.83 (42.08% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 10.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
168.81%
12-Months-Change
Fundamentals
Return on Equity
-30.98%
Trailing 12-Months
Asset Growth
-13.55%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Management Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
---
CGEM Stock 12 Month Forecast
Average Price Target
$33.83
▲(42.08% Upside)
Technical Analysis
Best Analysts Covering CGEM
1 Year
1 Year Success Rate
7/8 ratings generated profit
1 Year Average Return
+128.00%
reiterated a buy rating 21 days ago
Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +128.00% per trade.
---